

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet 1 of 1				<b>Complete if Known</b> <del>#</del> 4	
				Application Number	09/700,906
				Filing Date	November 21, 2000
				First Named Inventor	Flad
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	62-661-50303

**OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	✓	SCHLEUTER <i>et al.</i> , "The Cell Proliferation-associated Antigen of Antibody Ki-67: A Very Large, Ubiquitous Nuclear Protein with Numerous Repeated Elements, Representing a New Kind of Cell Cycle-maintaining Proteins", <i>J. Cell Biol.</i> , (1993), 123(3), 513-22	
		MAESHIMA <i>et al.</i> , "Antisense Oligonucleotides to Proliferating Cell Nuclear Antigen and Ki-67 Inhibit Human Mesangial Cell Proliferation", <i>J. Am. Soc. Nephrol.</i> , October 1996 (1996-10), 7(10), 2219-2229	
	✓	UHLMANN <i>et al.</i> , "Antisense Oligonucleotides: A New Therapeutic Principle", <i>Chemical Reviews</i> , 1990, Vol. 90, No. 4, pp. 543-584	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.